Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study
Vanina Popova(Janssen (Belgium)), Jaskaran Singh(Neurocrine Biosciences (United States)), David Hough(Janssen (Belgium)), Malek Bajbouj(Klinik und Poliklinik für Psychiatrie und Psychotherapie), Patricio Molero(Clinica Universidad de Navarra), Eduard Vieta(Hospital Clínic de Barcelona), Madhukar H. Trivedi(Southwestern Medical Center), Michael E. Thase(Veterans Health Administration), Pilar Lim(Janssen (Belgium)), Husseini K. Manji(National Institutes of Health), Ella Daly(Janssen (Belgium)), Kimberly Cooper(Janssen (Belgium)), Christine Mazzucco(Janssen (Belgium)), Richard C. Shelton(University of Maryland, College Park), Rosanne Lane(Janssen (Belgium)), Wayne C. Drevets(Johnson & Johnson (United States))
Cited by 888
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
Subgenual prefrontal cortex abnormalities in mood disorders
|Nature|1997|2.7k
Brain structural and functional abnormalities in mood disorders: implications for neurocircuitry models of depression
|Brain Structure and Function|2008|2.2k
How mental health care should change as a consequence of the COVID-19 pandemic
|The Lancet Psychiatry|2020|1.9k